Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients

• Status: Not yet recruiting
• Trial end date: 2025-04-02
• Target enrollment: 0
• Participant gender: All

Summary

Morbid obesity, is known to be associated with a high risk of VTE and, unfortunately, fixed doses of anticoagulant regimens may not provide optimal VTE prophylaxis in these patients especially after surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hawler Medical University
• Treatments: Bemiparin; Heparin, Low-Molecular-Weight

Criteria

Inclusion Criteria:

1. Participants required surgical intervention in: general surgery, orthopedic, neurosurgery, gynecology, bariatric surgery

2. Moderate, high, and very high risk for venous thromboembolism according to Caprin RAM

3. Participant is willing and able to give informed consent for participation in the study.

4. BMI ≥40kg/m2

Exclusion Criteria:

1. Having any contraindication to LMWH, such as active bleeding, history of heparin-induced thrombocytopenia , baseline platelet count <75 × 108/μl, severe renal disease (glomerular filtration rate <30 ml/minute), severe liver disease, or uncontrolled hypertension (>200/120 mmHg)

2. Known hypersensitivity to unfractionated or LMWHs

3. On oral or parenteral anticoagulants within 5 days before surgery

4. Severe arterial hypertension

5. Unable to comply with the study treatment and/or follow-up

6. Receiving prohibited medications

7. Pregnancy or lactation mother